# An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

> **NCT07665723** · PHASE1 · RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 25 (estimated)

## Conditions studied

- Active Ulcerative Colitis

## Interventions

- **DRUG:** Afimkibart
- **DRUG:** Caffeine
- **DRUG:** Warfarin
- **DRUG:** Omeprazole
- **DRUG:** Dextromethorphan
- **DRUG:** Midazolam
- **OTHER:** Vitamin K

## Key facts

- **NCT ID:** NCT07665723
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-29
- **Primary completion:** 2027-07-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07665723

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07665723, "An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07665723. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*